Extract
Bronchiectasis presents a significant burden of disease for patients, their families and healthcare services, with recurrent hospital admissions and poorer health-related quality of life, in addition to higher rates of fatigue, depression and cardiovascular disease [1–3]. The increasing prevalence and burden of bronchiectasis is recognised worldwide [3–6]. Patient education is a fundamental part of long-term management planning, as highlighted in the new European Respiratory Society guidelines, yet there is a lack of information available to patients in comparison to other chronic respiratory conditions.
Abstract
Improvements in information for those living with bronchiectasis should use patient-driven co-development processes http://ow.ly/vWCB30iCn2M
Acknowledgements
We would like to acknowledge Holly Ainsworth for assistance with using statistical software for the analysis of the BRIEF study data, and the staff of the William Leech Centre for Lung Research at the Freeman Hospital in the recruitment and study visit conduct in the BRIEF study. We also thank the participants. Author contributions: KH is the first and corresponding author of this article. TR, JN, VR and ADS were contributors to the manuscript and all authors read and approved the final manuscript.
Footnotes
Support statement: K.L.M. Hester is funded by a National Institute for Health Research Doctoral Research Fellowship (DRF-2012-05-149). This article presents independent work funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. A. De Soyza acknowledges funding to the BronchUK network from the UK Medical Research Council (grant MR/L011263/1) and a prior Higher Education Funding Council (HEFCE senior lectureship). Funding information for this article has been deposited with the Crossref Funder Registry.
Conflict of interest: K.L.M. Hester reports grants from NIHR, during the conduct of the study.
Conflict of interest: J. Newton reports grants from NIHR, during the conduct of the study.
Conflict of interest: T. Rapley reports grants from NIHR, during the conduct of the study.
Conflict of interest: A. De Soyza reports non-financial support from AstraZeneca (Bronchiectasis Interest Group meeting support), Novartis (in kind support for analysis in bronchiectasis) and Forest labs (Bronchiectasis Interest Group meeting support); personal fees from Bayer (speakers/advisory boards on bronchiectasis) and AstraZeneca (speakers/advisory boards on COPD); personal fees and other (advisory boards on bronchiectasis and in kind bench science support) from Novartis; other from Chiesi (travel bursary to attend ERS meeting), Almirall (travel bursary to attend ERS meeting) and Boehringer Ingelheim (travel bursary to attend BTS meeting); and grants from AstraZeneca (travel bursary to attend ATS meeting), all outside the submitted work. A. De Soyza has received medical education grant support for a UK bronchiectasis network from GSK, Gilead, Chiesi and Forest labs. A. De Soyza's employing institution receives fees for his work as coordinating investigator in a phase III trial in Bronchiectasis sponsored by Bayer.
- Received November 20, 2017.
- Accepted February 7, 2018.
- Copyright ©ERS 2018